282 related articles for article (PubMed ID: 17582309)
1. [Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines].
Gamelin E; Boisdron-Celle M; Morel A
Therapie; 2007; 62(2):99-103. PubMed ID: 17582309
[TBL] [Abstract][Full Text] [Related]
2. [Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
Deenen MJ; Cats A; Mandigers CM; Soesan M; Terpstra WE; Beijnen JH; Schellens JH
Ned Tijdschr Geneeskd; 2012; 156(48):A4934. PubMed ID: 23191966
[TBL] [Abstract][Full Text] [Related]
3. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Mercier C; Ciccolini J
Clin Colorectal Cancer; 2006 Nov; 6(4):288-96. PubMed ID: 17241513
[TBL] [Abstract][Full Text] [Related]
4. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Ostapowicz A; Dołegowska B
Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
[TBL] [Abstract][Full Text] [Related]
5. [Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine].
Boisdron-Celle M; Morel A; Gamelin E
Ann Biol Clin (Paris); 2010; 68(1):27-32. PubMed ID: 20146975
[TBL] [Abstract][Full Text] [Related]
6. [A case of dihydropyrimidine dehydrogenase (DPD) deficiency with severe side effects from UFT/Uzel administration].
Kai K; Endo Y; Yoshida K; Morikawa T; Nobuhisa T; Watanabe T; Matsumoto Y; Yamada T; Doi Y; Nakashima A; Nagahiro W; Ishizuka S; Sato S; Nakashima A; Nabeyama A
Gan To Kagaku Ryoho; 2008 Feb; 35(2):339-41. PubMed ID: 18281779
[TBL] [Abstract][Full Text] [Related]
7. Should DPD analysis be required prior to prescribing fluoropyrimidines?
Yen JL; McLeod HL
Eur J Cancer; 2007 Apr; 43(6):1011-6. PubMed ID: 17350823
[TBL] [Abstract][Full Text] [Related]
8. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
[TBL] [Abstract][Full Text] [Related]
9. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
Loganayagam A; Arenas-Hernandez M; Fairbanks L; Ross P; Sanderson JD; Marinaki AM
Cancer Chemother Pharmacol; 2010 Jan; 65(2):403-6. PubMed ID: 19795123
[TBL] [Abstract][Full Text] [Related]
10. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Saif MW; Diasio R
Clin Colorectal Cancer; 2006 Jan; 5(5):359-62. PubMed ID: 16512996
[TBL] [Abstract][Full Text] [Related]
11. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
12. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
Caudle KE; Thorn CF; Klein TE; Swen JJ; McLeod HL; Diasio RB; Schwab M
Clin Pharmacol Ther; 2013 Dec; 94(6):640-5. PubMed ID: 23988873
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Diasio RB
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
[TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
Boisdron-Celle M; Remaud G; Traore S; Poirier AL; Gamelin L; Morel A; Gamelin E
Cancer Lett; 2007 May; 249(2):271-82. PubMed ID: 17064846
[TBL] [Abstract][Full Text] [Related]
16. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
[TBL] [Abstract][Full Text] [Related]
17. Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.
Sadahiro S; Suzuki T; Maeda Y; Ishikawa K; Tanaka Y; Yasuda S; Kamijo A; Makuuchi H; Murayama C
Chemotherapy; 2007; 53(6):442-5. PubMed ID: 17952005
[TBL] [Abstract][Full Text] [Related]
18. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
19. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
